Waarom stijgt de aandelenkoers van ELI LILLY AND CO?
Bulls zeggen
Clinical trial efficacy
Phase 2 data for the eloralintide plus tirzepatide combination set a new efficacy benchmark by delivering strong weight loss and improved blood sugar control, which could differentiate Lilly's obesity franchise from competitors.
Next-generation obesity drug adoption
Retatrutide's best-in-class weight-loss results combined with a clean tolerability profile suggest broad adoption potential in patients with type 2 diabetes, expanding the addressable market for obesity therapies.
Access channel expansion
Survey evidence indicates the Medicare Bridge is increasing patient volume at obesity clinics and shifting some patients from cash-pay to a lower-cost channel, supporting potential revenue growth through higher treatment penetration.
Dose-dependent tolerability
Higher discontinuation rates at the highest combination doses raise tolerability concerns that may require dose optimization and could limit use of the most effective regimens.
Program execution risk
Operational frictions, including uncertainty about future program coverage and patient confusion about how the Bridge program works, could slow enrollment and reduce expected uptake.
Pricing and revenue mix pressure
Most Foundayo prescriptions starting at low doses create the risk that many patients remain on lower-priced regimens, which may cap realized prices and limit revenue per patient.
